Altre lingue Kintor Pharmaceutical Limited

Azioni

9939

KYG5273B1077

Tempo differito Hong Kong S.E. Altri mercati azionari 08:31:02 08/05/2024			Variaz. 5gg	Var. 1 gen.
1,08 ^HKD	+1,89%		+1,89%	-33,74%

22/04	Kintor Pharmaceutical Limited annuncia che lo studio clinico di fase II di GT20029 per il trattamento dell'alopecia androgenetica in Cina ha raggiunto l'endpoint primario	CI
28/03	Kintor Pharmaceutical Limited riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	22/04
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	22/04
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator	01/02
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	01/02
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30%	27/11
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	27/11
Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	28/10/23
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11/10/23
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11/10/23
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	28/08/23
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial	23/08/23
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	22/08/23
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	22/08/23
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	20/07/23
Kintor Pharmaceutical Enrolls First Patient for Phase III of Alopecia Drug Trial	20/07/23
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826	19/07/23
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary	12/05/23
Kintor Pharmaceutical's Completes US Phase 2 Trials of Alopecia Treatment; Shares Fall 4%	12/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kintor Pharmaceutical Limited

Azioni

9939

KYG5273B1077

Altre lingue

Filtri